Aventis Lovenox Promotions Challenged By Coagulation Test Maker
Executive Summary
A diagnostics company that developed a coagulation test for use with Lovenox alleges Aventis is falsely promoting the antithrombotic as requiring "no routine monitoring" and being "therapeutic from dose one.
You may also be interested in...
Aventis Lovenox Claims “False”; Corrective Ads Not Needed, Court Rules
Aventis does not have to run corrective advertisements for two Lovenox marketing claims that were false but have since been discontinued, a federal judge ruled April 29
Aventis Lovenox Claims “False”; Corrective Ads Not Needed, Court Rules
Aventis does not have to run corrective advertisements for two Lovenox marketing claims that were false but have since been discontinued, a federal judge ruled April 29
Aventis Lovenox Patent Defense: Re-Issuance Higher Priority Than Stay
Aventis' Lovenox generic defense remains centered on the re-issuance of an enoxaparin patent as the company defends the original version against potential generic competition